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Cystic fibrosis (CF) is a life-shortening disease with significant morbidity. Despite overall improvements in survival, patients with CF experience
frequent pulmonary exacerbations and declining lung function, which often accelerates during adolescence. New treatments target steps in the
pathogenesis of lung disease, such as the basic defect in CF (CF Transmembrane Conductance Regulator [CFTR]), pulmonary infections,
inflammation, and mucociliary clearance. These treatments offer hope but also present challenges to patients, clinicians, and researchers.
Comprehensive assessment of efficacy is critical to identify potentially beneficial treatments. Lung function and pulmonary exacerbation are the most
commonly used outcome measures in CF clinical research. Other outcome measures under investigation include measures of CFTR function;
biomarkers of infection, inflammation, lung injury and repair; and patient-reported outcomes. Molecular diagnostics may help elucidate the complex
CF airwaymicrobiome. As new treatments are developed for patients with CF, efforts should bemade to balance treatment burdenwith quality of life.
This review highlights emerging treatments, obstacles to optimizing outcomes, and key future directions for research.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Emerging treatments; Improved outcomes
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Cystic fibrosis (CF) is an autosomal recessive genetic
condition with an incidence of approximately 1:3500 in most
European and North American countries and 1:5000 to
1:20,000 in Latin America, the Middle East, and South Africa
[1]. Progressive obstructive lung disease causes over 90% of
deaths in patients with CF [2]. The pathophysiology of CF is
outlined in Table 1. Mutations in the gene coding for the CF
Transmembrane Conductance Regulator (CFTR) result in an
absent or dysfunctional protein at the surface of certain epithelia
[3]. CFTR normally regulates ion (chloride and sodium) flux
across the cell membrane. In the lungs, the mechanism by which
CFTR dysfunction leads to the characteristic lung disease of CF
is complex. The predominant theory is that CFTR dysfunction
causes dehydration of the airway surface liquid and impairment
of mucociliary clearance [4]. Chronic respiratory infections
follow, leading to inflammation and progressive lung destruc-
tion. Other potential effects of CFTR dysfunction include
activation of host inflammatory response, defects in bacterial
phagocytosis by airway macrophages, changes in antimicrobial
properties of airway mucus, and alterations of sodium transport
across the epithelial sodium channel (ENaC) [5–7]. Patients
with CF are susceptible to opportunistic bacteria, most notably
Pseudomonas aeruginosa [8]. Chronic infection with the
mucoid phenotype of P. aeruginosa is associated with
shortened survival [9]. A wide variety of other microbes has
also been found in the airways of patients with CF [10].
Current CF treatments target respiratory infections, inflam-
mation, mucociliary clearance, and nutritional status. Many
new therapies are in development, including molecules aimedat the basic defect in CF [11]. One of the biggest challenges in
CF research is identifying valid and sensitive, age appropriate
biomarkers that assess response to therapies [12]. Forced
expiratory volume in 1 s (FEV1) and pulmonary exacerbation
rate are the most commonly used outcomes in CF clinical trials.
As improvements in treatment slow pulmonary function
decline, the utility of FEV1 and exacerbation rate as outcome
measures may decrease. CF-specific patient-reported out-
comes have been validated for use in clinical trials and are
currently being included as either primary or secondary
outcomes if they meet regulatory approval [13,14]. Other
outcome measures that will likely be important in future
studies include measures of CFTR function (sweat chloride
concentration and transepithelial potential difference), chest
imaging (standard chest radiography and high-resolution
computed tomography [CT]), inflammatory markers, and
microbial biomarkers [15].
Patients with CF and their care providers face many
obstacles including uncertainty or lack of information about
best therapies, high treatment burden and substantial medical
expenses [16]. As new treatments become available, these
challenges will only increase. The best application of all
potential therapies needs to be determined while balancing
treatment burden and quality of life. We convened an expert
panel to review current outcomes, goals of therapy, key
barriers to treatment, and research opportunities. This
manuscript, resulting from the expert panel meeting, is not
meant to be a comprehensive review of the treatment of
pulmonary disease in patients with CF. Rather it is focused on
key areas of research and opportunities for improving the
treatment of CF patients.
Table 1
Pathogenesis, treatments, and outcome measures for cystic fibrosis (CF) lung disease.
Step in pathogenesis Treatment Biomarker/outcome measure
CFTR mutation Gene therapy Transgene/protein expression
CFTR protein absence/dysfunction Read-through of stop mutations (PTC 124) Sweat chloride
Correctors (Vertex 809) Nasal potential difference
Potentiators (Vertex 770) Rectal potential difference
Tissue expression of mature CFTR
Abnormal ASL/mucociliary clearance Mannitol dry powder Mucociliary clearance
Dornase alfa
Hypertonic saline
Airway clearance treatments
Infection colonization–exacerbation Antimicrobials: IV, inhaled Number of exacerbations
PA eradication Bacterial quantification
Molecular diagnostics/microbiome shifts
Antimicrobial susceptibility
Serology for pathogens
Inflammation Macrolides (azithromycin) Serologic/sputum inflammatory markers
NSAIDs (ibuprofen)
Lung destruction All of the above FEV1, lung volumes and other measures of lung function
Lung structural abnormalities High-resolution CT scan
Biomarkers of lung tissue breakdown
Lung clearance index
Morbidity/mortality All of the above Patient-reported outcomes
Hospitalizations
Measures of treatment burden
ASL = airway surface liquid; CFTR = Cystic Fibrosis Transmembrane Conductance Regulator; CT = computed tomography; FEV1 = forced expiratory volume in 1 s;
IV = intravenous; NSAIDs = nonsteroidal anti-inflammatory drugs; PA = Pseudomonas aeruginosa.
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2.1. Survival
The Cystic Fibrosis Foundation (CFF) Patient Registry
includes data on approximately 24,500 patients with CF in the
United States [17]. Median predicted survival in 2007 calculated
via a standard life table analysis was 37.4 years. However, the
median age at death, a metric that has not increased to the same
extent as the median predicted survival, was 25.9 years.
Approximately 25% of deaths occurred in children, adolescents,
and young adults≤21 years of age. Data from the German Cystic
Fibrosis registry in 2005 showed similar survival figures with
median age at death of 23.7 years and the median cumulative
survival 37.4 years [18]. In 2005, 17.6% of deaths recorded in the
German registry occurred in patients less than 18 years of age.
Similar survival data have also been reported in France [19].
Further research into the causes and potential preventivemeasures
for early deaths is needed.
2.2. Lung function and body mass index
As noted from an analysis of the CFF Patient Registry in
2007, improvements were seen in several markers of disease
severity, including mean body mass index (BMI) and mean
FEV1 (% predicted), compared with 1990 (Fig. 1a,b) [17]. In
this analysis, lung function and BMI were higher at each age.
Nonetheless, BMI (percent predicted) peaks during early
childhood followed by a steady decline in school-age children
and adolescents. Lung function (percent predicted) is main-tained relatively well during the first decade of life and then
declines steeply beginning around the age of 12 years.
The association of better nutritional status with improved
lung function is well documented [20–23], and poor nutrition is
a risk factor for accelerated decline in lung function [24]. Data
from 6835 CF patients in the German CF Registry from 1995 to
2005 found that low BMI (b19 kg/m2) and low FEV1 (b80%)
correlated with mortality [18]. It is not known whether the
decline in BMI predates the FEV1 decline in individual patients.
There may be periods of time that children are at particular risk
for decline (e.g., BMI decline in school-age children and FEV1
decline in adolescents). Identifying these high-risk periods may
help focus interventions.
Studies of lung function decline provide essential information
for clinical care and research. Understanding the mechanisms of
lung injury and risk factors for lung function decline may guide
choices in clinical care and development of new therapies.
Defining the rate of lung function decline in patients with CF is
also important as a reference for assessing therapies and designing
clinical trials [25]. A recent retrospective study by McPhail et al.
compared lung function and nutritional outcomes in 144 patients
with CF divided into two birth cohorts [26]. The authors found
substantial improvements in lung function and nutritional
outcomes (weight, height, and BMI percent predicted) and a
significant decrease in the rate of FEV1 decline from the ages of
6 to 12 years in the latter cohort. Although the study was
retrospective, it is the first to demonstrate a change in the rate of
lung function decline between birth cohorts. The decreased rate of
lung function decline was associated with a higher baseline BMI
(percent predicted) and slower rate of BMI decline.
Fig. 1. a. Mean Centers for Disease Control (CDC) body mass index (BMI)
percentiles versus age with 95% confidence intervals. BMI was higher at each
age in 2007 compared to 1990. CFF Patient Registry Data [16]. b. Mean forced
expiratory volume in 1 s (FEV1) percent predicted versus age with 95%
confidence intervals. Lung function was higher at each age in 2007 compared to
1990. Data from CFF Patient Registry, 1990 and 2007 [16].
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steady improvements, the frequency of pulmonary exacerbations
remained unchanged from 1990 to 2007 (B. Marshall, MD, oral
communication, 2009). Whether this finding is due to lack of
impact from current interventions on exacerbation frequency,
changes in the definition of exacerbation, or a tendency toward
more aggressive therapy is not known. Emerging research
suggests that exacerbations play a large role in the overall decline
in lung function, which may not return to baseline following
exacerbation [27]. Understanding practice patterns for exacerba-
tion treatment and outcomes following therapy will guide future
clinical care guidelines. Applying a consistent definition of
exacerbation is also important for use as an outcome measure in
clinical trials.
2.3. Newborn screening
Newborn screening for CF began in the 1980s in several
countries including Australia, several European countries, and
parts of the United States [28,29]. The recommendation in 2004
by the US Centers for Disease Control and Prevention in favorof newborn screening led to the rapid implementation of testing
across the United States. Forty-eight states now screen for CF
and the remaining two states will begin screening by 2010 [30].
The European CF Society recently published best practice
guidelines for newborn screening in anticipation of increased
screening programs across Europe [31]. Between 2004 and
2008 the number of infants screened in European countries
increased from 1.6 to 3 million, and this increase is expected to
continue. Many of the screening programs in Europe are
regional rather than national, reflecting geographic and ethnic
variations [32,33]. Screening protocols vary between programs
necessitating guidelines for future program implementation.
Widespread implementation of newborn screening in the US is
reflected in the proportion of newborn screen diagnoses
recorded by the CFF registry . Prior to 2005, less than 15% of
all new cases were diagnosed by newborn screening. By 2007,
more than 30% of new cases were diagnosed by newborn
screening [17], and this number is expected to increase over the
next few years. Because screening detects infants with CF who
are asymptomatic, changes to current infant care guidelines are
needed. Rather than focusing on the treatment of problems such
as failure to thrive and pulmonary exacerbation, care of infants
with CF should reflect more preventive treatments such as
nutritional intervention with pancreatic enzyme replacement
therapy and fat soluble vitamin supplements to achieve and
maintain normal growth and development [34]. Studies from
the Wisconsin newborn screening program clearly show that
early intervention improves nutritional outcomes, and there is
some evidence of improved overall survival in newborns
diagnosed before 1 month of age compared with infants
diagnosed later [35–38]. Important questions remain regarding
optimal treatment to prevent lung disease and to ensure normal
growth and nutrition. Studies are now underway to assess
pulmonary therapies and nutritional interventions in infants and
toddlers; patient-reported outcomes in this young population are
also currently being validated [39].
2.4. Adolescents
Lung function decline appears to accelerate during adoles-
cence. Understanding factors that contribute to this decline is
important for developing effective therapeutic approaches.
Konstan et al. examined a subset of data collected for the
Epidemiologic Study of Cystic Fibrosis (ESCF), a prospective
observational study designed to characterize the natural history
of CF [24]. Data from 4923 patients aged 6 to 17 years were
examined to characterize the change in FEV1 percent predicted
over 3 to 6 years and to identify risk factors for FEV1 decline
among patients in three age groups (6 to 8 years, 9 to 12 years,
and 13 to 17 years). Children 6- to 8-years-old had a slower rate
of lung function decline compared with patients in the other two
groups. Risk factors for decline in lung function for all three age
groups were high baseline FEV1, female gender, and crackles
on auscultation. P. aeruginosa was a risk factor for decline in
the 6- to 8-year-old and 9- to 12-year-old groups.
Other possible contributors to lung function decline in
adolescence are the onset of CF-related diabetes and infection
Fig. 2. Multifactorial causes of variability in outcomes. CFTR = Cystic Fibrosis
Transmembrane Conductance Regulator. Adapted from original provided by
Michael Schechter, MD, Emory University, Atlanta, GA, USA.
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aureus (MRSA),P. aeruginosa and other gram-negative bacteria,
fungi and nontuberculous mycobacterium [40,41]. In addition,
adherence to treatments has been shown to decline in this age
group [42,43]. Adolescents are often balancing academic
demands and pressure to fit in with peers with time-consuming
pulmonary treatments such as inhaled tobramycin, dornase alfa,
and hypertonic saline. Rates of depression and anxiety are also
high during adolescence, contributing to worse compliance [44].
Compared with younger children, adolescents often receive less
parental supervision of their treatment regimen, which has been
shown to reduce the frequency and duration of therapies [45].
Understanding which factors are most strongly related to lung
function decline would allow patients and caregivers to focus on
the most important therapies for this age group, and thus preserve
lung function through this critical life stage.
2.5. Adults
Just as the landscape for infant care in CF is changing, so is the
care of adults with CF. As survival has improved, the number of
patients with CF reaching adulthood has expanded dramatically.
Between 1985 and 2007, the number of patients≥18 years of age
in the CFF Patient Registry increased from 4000 to more than
10,000 [17]. The number of adult CF programs has also
expanded, although more adult CF physicians and programs are
needed. Importantly, a shift in the clinical phenotype of these
patients has also occurred. In 1985, 32% of 18-year-old patients
were classified as havingmild or no lung disease (FEV1≥70% of
predicted) and 33% were classified as having severe lung disease
(FEV1b40% of predicted). In 2007, 67% of 18-year-old patients
hadmild or no lung disease, and only 7.6% of patients had disease
classified as severe. Clinical approaches to adults with mild lung
disease are needed to preserve lung function while maximizing
quality of life.
3. Barriers to care
The treatment goals for patients with CF lung disease are to
halt or slow disease progression by maintaining FEV1 and
preventing pulmonary exacerbations, to provide symptom
relief, and to improve quality of life. As discussed above,
despite the availability of proven therapies, significant variabil-
ity exists in these outcomes and the use of medications. Many
issues likely contribute to this variability, including genetic,
medical, and environmental factors (Fig. 2). Understanding how
these factors affect outcomes and addressing the barriers to care
is a critically important task. In an attempt to identify existing
barriers, we considered specific obstacles facing patients,
clinicians, and researchers (Table 2). By targeting barriers in
each group for intervention, we hope to advance the develop-
ment and delivery of CF care.
3.1. Barriers for patients
Patients with CF and their families face many barriers
including (i) large treatment burden that may make adherencedifficult, (ii) financial challenges, (iii) lack of education around
illness or limited understanding of disease process and
(iv) depression and/or anxiety [16,44,46]. CF places a large
treatment burden on patients and their families with complex,
time-intensive therapies and multiple medications administered
throughout the day. Patients with chronic P. aeruginosa infection
who are receiving inhaled tobramycin and dornase alfa likely
spend several hours on treatments just to maintain health during
times of clinical stability. A recent study of adults with CF found
that perceived treatment burden was highly associated with the
number of nebulized medications prescribed [47]. Subjects
reported spending an average of 108 min (SD±58 min) on
daily CF treatments. In addition, lengthy hospitalizations, which
are commonplace in treatment plans, are disruptive to families,
schooling, work, and extracurricular activities [48].
Poor adherence to therapy is very common and the likeliest
cause of treatment failure [49]. In addition to the high treatment
burdens that limit adherence, families may have a poor
understanding of how specific medications work or how to
correctly administer them. As CF care is complex, with multiple
treatments targeting different pathophysiologic processes, it is
easy for families to feel overwhelmed. With improved survival in
CF, families may not fully understand the seriousness of the
disease, the need for daily preventive therapies, and the risks
associated with poor adherence. Consequences of poor adherence
are often seen more over the long term than immediately (i.e.,
exacerbation after months of noncompliance is more common
than an immediate increase in symptoms), so the cause-and-effect
relationship may not be obvious. Furthermore, adolescents often
face peer-pressure and may resist any intervention that differ-
entiates them from their peers. New adherence interventions
targeting these issues have been developed and are being
evaluated for use in clinical settings [50,51].
Adherence is also strongly affected by the cost of therapy.
Although most patients with CF in the US have some form of
health insurance, many have inadequate coverage. The increasing
Table 2
Barriers to optimal therapy.
Patients/families Medical care providers Researchers
Adherence Lack of resources/time Identifying appropriate outcome measures
Treatment burden Lack of time Need for large sample size
Mental health/depression Implementation of guidelines/evidence-based medicine Appropriate selection of controls
Lack of insurance, underinsurance Drug interactions Navigating regulatory guidelines
Lack of understanding (disease seriousness,
treatment benefits, etc)
Relaying hope vs. seriousness of disease
Managing treatment failures, adverse events
Balancing need for new therapies
with patient safety
Heterogeneity of response/pharmacogenetics Lack of resources/time
Competing clinical trials
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hospitalizations, and procuring medications difficult or impossi-
ble for some families. Patients classified as underinsured often do
not fulfill the CFF Clinical Care Guidelines' recommendation for
quarterly clinic visits and may not be hospitalized for pulmonary
exacerbations even when needed [52]. Patients with low
socioeconomic status are at a particularly high risk for inadequate
resources and poor adherence. In many other countries, access to
health insurance is much better than in the US; thus CF patients in
these countries may not face these same barriers to treatment [53].
The consequences of poor adherence include increased symp-
toms, accelerated decline in lung function, more frequent
hospitalizations, increased family stress and conflict, and higher
healthcare costs [43]. A new clinical study now underway will
implement an adherence intervention using prescription refill
histories as the primary outcome. (A. Quittner, MD, oral
communication, 2009).
Symptoms of depression and anxiety are common among
patients with CF and parent caregivers, as has been found in
many chronic illnesses [44]. Rates of depression in adults with
CF range from 29% to 46%, and similar rates have been
documented in parent caregivers, although at least one study of
adult CF subjects found no increase in anxiety and depression
(30% and 13% respectively) compared to published normative
data [54]. Other studies however have found that adolescents
with CF have higher rates of depression than the general
population [44]. Importantly, patients with depression are less
likely to adhere to their therapies, more likely to miss clinic
visits, engage in more risky behaviors, including smoking and
illicit drug use, and report worse quality of life. A recent study
by Quittner et al. showed a link between depression in parent
caregivers of children with CF, decreased compliance with
enzyme therapy, and decreased weight in these children at the
next clinic visit [55]. The International Depression/Anxiety
Epidemiological Study (TIDES) is an ongoing, international
epidemiologic study, recruiting 3600 patients and caregivers,
aimed at establishing the prevalence of depression and anxiety
in adolescents and adults with CF and in caregivers of children
with CF.
3.2. Barriers for clinicians
CF clinical care providers face barriers to providing optimal
care. A lack of resources can significantly affect the clinician's
ability to adhere to best care practices. Resources needed toensure optimal care for patients with CF include adequate clinic
space and a dedicated CF team with nurses, a nutritionist, social
workers, pharmacists, and respiratory therapists, as well as
ancillary support from psychology, clinical laboratories (mi-
crobiology, chemistry, molecular diagnostics), radiology, and
pulmonary function testing [56,57]. Smaller CF centers may
have particular difficulty supporting a CF team and ancillary
staff. Providers also face many time constraints. Confronted
with complex medical care, it may not be possible to adequately
address all issues in the time allotted, and assessing patient
compliance is difficult, as self-reported adherence typically
represents an overestimation [58].
With the expansion of care guidelines and new therapies,
staying current with new developments and recommendations
may be difficult. Many disciplines, including pulmonary and
critical care medicine utilize protocols to improve delivery of
care [59,60]. Protocols lead to less variability in care and remind
clinicians of all therapies that may apply to particular patients
[61]. Quality improvement projects in CF are standardizing
clinician education and adherence to practice guidelines with
positive results. Data from these protocols and projects
demonstrate that clinical improvements can occur without
losing individualization of medical care [62–64].
As new therapies are approved, clinicians will have to decide
how to incorporate these treatments into existing regimens.
Whether new treatments should be used as additive or as
replacements for existing therapies is unknown. Patients who
develop adverse effects from medications or who do not
respond to particular treatments are particularly challenging.
Identifying biomarkers that distinguish patients who may not
respond to particular treatments will allow better individuali-
zation of therapies. Whether biomarkers similar to those used in
research studies will be useful in managing the care of
individual patients needs to be examined. Adverse events and
toxicities from medications are frequent challenges for
clinicians. Risk of renal injury from aminoglycosides, for
example, is increased with higher doses, high cumulative
lifetime exposure, concurrent use of other nephrotoxic medica-
tions such as nonsteroidal anti-inflammatory drugs (NSAIDs),
and preexisting kidney disease from CF-related diabetes,
dehydration, or immunosuppression after lung transplantation
[65,66]. Once-daily dosing of intravenous tobramycin appears
to have equal efficacy but less nephrotoxicity in children with
CF compared with TID dosing [67]. Vestibular toxicity and
ototoxicity are also common, but likely underappreciated,
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improves, monitoring and early detection of these complica-
tions will become increasingly important.
Finally, clinicians may struggle to communicate hope along
with the serious nature of CF. Families should be encouraged by
the major advances in CF care and the great improvements
made in life expectancy. However, these advances come with a
high cost in daily treatment burden and toxicities. Communi-
cating the sense of urgency for preventive and aggressive care
along with an attitude of optimism can be challenging. Open,
frequent, and clear communication with families about risks and
benefits of both treatment and lack of treatment is essential.
3.3. Barriers for researchers
Research into new, improved therapies in CF is needed to
build on current advances. CF researchers face obstacles similar
to those of clinicians in terms of the lack of time and resources.
With so many treatment options currently in or approaching
clinical trials, a lack of eligible study subjects and qualified CF
research teams may be a barrier. Clinical research must balance
the urgent need for new therapies with deliberate research
studies that allow careful, reproducible and reliable assessment
of patient safety and an adequate understanding of benefits.
One of the biggest challenges facing CF clinical research is
the need for sensitive biomarkers and outcome measures for use
in clinical trials [70]. Outcome measures can be categorized as
[1] clinical efficacy measures (pulmonary exacerbations,
hospitalizations, antibiotic use, growth parameters, patient-
reported outcomes, and quality-of-life measures), [2] surrogate
endpoints (FEV1, chest x-ray or chest computed tomography
(CT) scan, infant and preschool lung functions, lung clearance
index), and [3] biomarkers (microbial cultures, inflammatory
markers, CFTR functional measures such as nasal potential
difference and sweat chloride) [12]. Clinical efficacy endpoints
are defined by the FDA as “a characteristic or variable that
reflects how a patient feels, functions, or survives” and are
generally required for trials seeking FDA approval [71].
Previous phase III CF clinical trials used lung function
(FEV1) and pulmonary exacerbations as key outcome measures.
As new, approved therapies result in improved outcomes, these
measures may become less sensitive in detecting a difference
between treatment groups [12]. Appropriate selection of
outcome measures for clinical trials depends on the population
under study (infants versus adolescents or adults), severity of
disease, and therapeutic target under investigation (CFTR
modulation, airway infection, mucociliary clearance). With
the expansion of newborn screening and emphasis on early,
preventative care in CF, finding sensitive, precise and feasible
clinical outcome measures for young children (b6 years) is
critical [72]. Current outcome measures under investigation
include infant pulmonary function testing (plethysmography,
gas dilution and raised volume rapid thorocoabdominal
compression techniques), preschool pulmonary function testing
(spirometry, force oscillometry, lung clearance index measured
by multiple-breath washout, and measures of airway resistance),
chest CT, and bronchoalveolar lavage for microbial culture andinflammatory biomarkers. Chest CT imaging may be more
sensitive than lung function in detecting early structural changes
in the lung and peripheral airway disease [73].
In older children and adolescents outcome measures include
clinical efficacy endpoints such as pulmonary exacerbations,
hospitalizations, patient-reported outcomes (PROs) and quality-
of-life measures [13]. Older patients are more likely to
spontaneously expectorate sputum or tolerate sputum induction,
allowing analysis of microbiologic and inflammatory biomar-
kers [74]. Given concerns about adherence to therapies,
measures of compliance including patient diaries, pharmacy
refill reports and electronic monitors may also provide useful
data from clinical trials [58]. For outcome measures in all age
groups, standardization of operating procedures and equipment
is vital, especially when performing multi-center clinical trials.
The CFF is now working with researchers to bank sputum and
plasma specimens from participants in clinical trials. Such
specimens would be available to researchers for future
microbiologic and protein biomarker studies.
Patient-reported outcomes (PRO) are increasingly important
[13] and have been approved by the FDA for use in clinical trials.
PROs evaluate changes in symptoms, perceptions of health, and
daily functioning as perceived by the patient. Measures range
from a single-item rating of pain to multidimensional, health-
related quality-of-life instruments. These measures improve our
understanding of how treatments impact CF symptoms and daily
functioning, e.g.: school attendance, and may be more sensitive
than physiologic measures such as FEV1. Over the past decade,
four CF-specific PRO measures have been developed, including
CFQ-R [14], the CF Respiratory Diary [75], CF QoL [76], and
Questions on Life Satisfaction [77]. Several of these measures are
validated and the minimal clinical important difference for the
CFQ-R has now been determined. Validation studies are also
under way for a preschool version of the CFQ-R.
3.4. Quality improvement and practice patterns
Major advances in CF care over the past 15 years include the
introduction of dornase alfa (DNase), tobramycin solution for
inhalation, high dose ibuprofen, chronic oral azithromycin, and
hypertonic saline therapy. Randomized placebo-controlled trials
for each of these therapies demonstrated significant improve-
ments in FEV1 and/or reduced pulmonary exacerbation or
hospitalization rates for treated patients compared with controls
[78–80]. Despite clear benefits, some patients are still not
receiving all appropriate therapies. The CFF Patient Registry
tracks chronic respiratory medication use in eligible patients.
Patients are considered eligible for treatment with dornase alfa
and hypertonic saline if they are aged≥6 years and for treatment
with inhaled tobramycin if they are P. aeruginosa positive and
aged ≥6 years. Patients considered eligible for chronic azithro-
mycin therapy are those aged ≥6 years with chronic
P. aeruginosa, weight ≥25 kg, FEV1 (percent predicted)
≥30% and no contraindications to treatment. In 2007, of those
eligible for therapy, 74% received dornase alfa, 34% received
hypertonic saline, 67% received inhaled tobramycin, and 63%
received chronic macrolides, with notable differences in use
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indicated therapies include (i) overall complexity of medical care,
(ii) a lack of provider education and patient understanding
regarding clinical indications for treatment, (iii) difficulty
adhering to these time-consuming treatments, (iv) poor tolerance
of certain medications and (v) financial burden in covering co-
payments or lack of insurance. Quality improvement initiatives at
many CF centers have sought to improve provider consistency
with standards of care. Challenges to implementing guideline
recommendations vary by center. Smaller centers may struggle
with a lack of resources, personnel, and time. Larger centers may
struggle with the bureaucracy often required to change practice
patterns. The CFF estimates that by providing currently available,
appropriate therapy to all patients with CF, significant improve-
ments in life expectancy could be made. Interventions to improve
patient adherence and tolerance of particular medications are
needed [43,58,81].
4. CF lung disease: therapeutic targets
4.1. Early Pseudomonas aeruginosa eradication
One of the most important advances in CF care is early
management of P. aeruginosa infection with the goal of bacterial
eradication from airway secretions [82]. Chronic P. aeruginosa
infection is associated with impaired lung function and decreased
survival in CF [83]. Multiple studies have shown that aggressive
antibiotic treatment at the time of initial P. aeruginosa detection
delays the time to chronic infection [84]. Hansen et al. recently
reviewed their 15 year experience using inhaled colistin and oral
ciprofloxacin for P. aeruginosa eradication [85]. At their center,
146 CF patients were followed for a median observation time of
7 years. Of those treated for a first ever P. aeruginosa isolate
during the study period, 80% remained free of chronic
colonization at the end of the study. Additional studies or early
P. aeruginosa eradication were reviewed in detail in a recent
article [86]. Although early treatment strategies are now used by
most CF centers, there is no agreement on optimal treatment [87–
90]. Published studies from the United States, the European
Union, Australia, and Canada have used various combinations of
intravenous antibiotics, oral ciprofloxacin, inhaled tobramycin,
and inhaled colistin for differing durations. However, comparing
approaches is complicated by the use of different study
populations and outcome measures.
Two large multi-center studies warrant mention. One study,
the Early Pseudomonas Infection Control (EPIC) study, is a
randomized trial in the United States assessing the efficacy and
safely of inhaled and oral anti-pseudomonal antibiotics following
the initial isolation of P. aeruginosa [91]. The second study,
EarLy Inhaled Tobramycin for Eradication (ELITE), is a multi-
center European study that assessed the duration ofP. aeruginosa
eradication following a 28- or 56-day course of inhaled
tobramycin. Preliminary results from this study show a high
rate of successful and durable eradication with no difference in
time to recurrence between treatment groups [92].
The increasing use of eradication strategies for P. aeruginosa
has raised the concern that overuse of antibiotics may lead tomultidrug-resistant P. aeruginosa infection [86]. A recent
retrospective study by Ho et al. compared the antibiotic
susceptibility of first and subsequent P. aeruginosa isolates
from patients with CF treated with eradication therapy [93]. The
study included patients treated with varied regimens of anti-
pseudomonal therapy over 10 years. They found no change in
susceptibility patterns of isolates following intensive treatment
and no difference between isolates that were successfully
eradicated and those that failed eradication. Microbial sensitiv-
ity indices will be important outcome measures in future studies
of eradication protocols. Other challenges in eradication therapy
that need to be studied include differentiating true eradication
from bacterial suppression, and assessing reinfection from
environmental sources.
4.2. Chronic Pseudomonas aeruginosa therapy
Both the overall and age-specific prevalence ofP. aeruginosa
appear to have decreased over the past decade, possibly
secondary to aggressive early eradication strategies [94].
However in 2007, more than 50% of patients with CF had a
positive culture for P. aeruginosa, and this number approached
80% for patients over the age of 25 years [17]. Currently, in the
US, there is only one Food and Drug Administration (FDA)-
approved therapy for patients with CF and chronic P. aeruginosa
infection: tobramycin solution for inhalation. Chronic, alternate-
month treatment with inhaled tobramycin has been shown to
improve lung function, decrease sputum P. aeruginosa bacterial
counts, and reduce hospitalizations in CF subjects with chronic
P. aeruginosa infection [79,95].
Chronic macrolide therapy is also beneficial in patients with
chronic P. aeruginosa infection. In a randomized placebo-
controlled trial, oral azithromycin (dosed three times a week for
24 weeks) improved lung function and reduced pulmonary
exacerbations in CF subjects with chronicP. aeruginosa infection
[78]. The mechanism of action of chronic macrolides is more
likely related to anti-inflammatory properties than to antimicro-
bial effects [96]. A randomized, placebo-controlled, multi-center
trial in France studied azithromycin in subjects regardless of
chronic P. aeruginosa status [97]. A significant reduction in
exacerbations and antibiotic use was demonstrated in the treated
group compared to placebo regardless of infection status.
Inhaled colistin is a frequently used alterative to inhaled
tobramycin and is considered first-line therapy for chronic
P. aeruginosa infection in the United Kingdom [98]. A
randomized one-month trial comparing tobramycin solution for
inhalation with inhaled colistin found no difference in the
reduction ofP. aeruginosa in culture, but significant improvement
in lung function in the inhaled tobramycin group [99]. The latter
result may have reflected previous exposure to the drug in the
colistin group and treatment with a 1MU rather than a 2MU dose.
An open-label follow-up to this study showed a persistent
advantage in lung function for the inhaled tobramycin group [100].
New antibiotic treatment options are needed for patients with
CF and chronic P. aeruginosa infection for several reasons.
First, some patients are unable to tolerate current inhaled
antibiotics due to allergic reactions or adverse effects [101,102].
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inhaled tobramycin and colistin require long daily nebulizer
treatments, which may reduce patient compliance. Finally,
some patients do not show expected or sustained benefit from
particular medications. For example, studies have shown a
heterogeneous response to azithromycin with some patients
improving significantly but others worsening, as measured by
FEV1 [103]. In addition to inhaled antibiotics for chronic use,
advances have been made in intravenous anti-pseudomonal
therapies, and several new treatments are now available. New
therapeutic options for P. aeruginosa, Burkholderia cepacia
complex, and other common CF pathogens are in clinical trials
(Table 3). Aztreonam lysine solution for inhalation (AZLI),
tobramycin powder for inhalation (TIP), and dry powder
colistin are currently in phase III trials and are discussed below.
4.3. Inhaled antibiotics: phase III trials
4.3.1. Aztreonam lysine for inhalation (AZLI)
Aztreonam is a monobactam antibiotic with activity against a
broad spectrumof gram-negative bacteria, includingP. aeruginosa,
currently approved for intravenous administration. Aztreonam
lysine (AZLI) was formulated specifically for inhalational use to
improve airway tolerability. The eFlow© electronic nebulizer was
designed to efficiently deliver AZLI in a relativelymonodispersed
particle spectrum (average delivery rate 2.5 ml/min). Phase Ia and
Ib pharmacokinetic and safety studies in healthy adults and
patients aged N12 years with CF demonstrated that doses up
to 225 mg were safe and well tolerated [104]. A multi-center
phase II randomized, placebo-controlled trial studied safety and
efficacy of 2 weeks of AZLI therapy in 105 subjects with CF
(age≥ 13 years), chronic P. aeruginosa infection, and
FEV1≥40% predicted [105]. Change in FEV1 did not reach
statistical significance, although there was a significant improve-
ment in FEV1 in a subset of patients with moderate lung disease
(FEV1≤75% of predicted).Table 3
New antimicrobial treatments in cystic fibrosis (CF).
Treatment Potential targe
PA eradication Early PA infec
Azithromycin in PA-negative patients Airway inflam
Fosfomycin MDR-PA
Tigecycline MRSA, MSSA
Aztreonam lysine for inhalation PA, possibly B
Tobramycin powder for inhalation PA
Fosfomycin: tobramycin inhalation PA, MRSA, M
Liposomal ciprofloxacin PA
Levofloxacin solution for inhalation PA
Liposomal amikacin PA, biofilm pe
Dry powder colistimethate PA
Ciprofloxacin PulmoSphere® inhalation powder PA
AZLI = aztreonam lysine solution for inhalation; BCC = Burkholderia cepacia com
Pseudomonas Infection Control Study; FDA = Food and Drug Administration; IV =
MDR-PA = multidrug-resistant Pseudomonas aeruginosa; MRSA = methicillin-re
aureus; PA = Pseudomonas aeruginosa; SM = Stenotrophomonas maltophilia.
a Information derived from www.clinicaltrials.gov.
b Information derived from Cystic Fibrosis Foundation Therapeutics.On the basis of phase II data, three phase III studies were
performed. Patients with CF≥6 years of agewith baseline FEV1
levels 25% to 75% of predicted and P. aeruginosa detected by
sputum culture were eligible for enrollment. In the first study
(AI-007), 164 patients were randomized to receive placebo or
AZLI 75 mg TID for 28 days [106]. Results demonstrated a
significant improvement in respiratory symptoms as measured
by a patient-reported outcome, the CF Questionnaire-Revised
(CFQ-R), and improvement in FEV1 (10.3%) in the treatment
group compared with the placebo group. A second phase III
study (AI-005) was designed to assess the safety and efficacy of
a 28-day treatment with AZLI and the ability of AZLI to
maintain or improve clinical status following a 28-day course of
tobramycin solution for inhalation in patients with CF [107]. A
total of 211 patients received a 28-day course of tobramycin
solution for inhalation, followed by randomization to placebo or
AZLI 75 mg BID or TID for 28 days. Results from this study
showed significant improvement for AZLI-treated patients
compared with placebo-treated controls in time to anti-
Pseudomonas antibiotic need, FEV1, and CFQ-R score.
Respiratory symptoms were the most commonly reported
adverse events, and occurred in similar rates in placebo and
treatment groups. A reduction in P. aeruginosa colony-forming
units from microbial culture was observed following AZLI
treatment in both studies.
An open-label follow-on study (AI-006) for patients who
participated in AI-007 or AI-005 evaluated the safety of
repeated 28-day alternate-month courses of AZLI over
18 months. 274 patients with CF were enrolled and received
AZLI 75 mg BID or TID. There was no evidence of increased
adverse events over repeated courses compared to a 28 day
course of AZLI. Patients receiving repeated courses of AZLI
demonstrated improvements in pulmonary function, CFQ-R
score, and decreased P. aeruginosa density in sputum compared
with baseline [108]. Several additional phase III studies are
underway in the European Union and the United States alongt Research phase
tion Multi-center trials (EPIC, a ELITE)
mation, bronchiectasis Phase IVa,b
FDA approved: non-CF indication
, BCC, MA, MC FDA approved: non-CF indication
CC Phase IIIa,b
Extended-access program
Phase IIIa,b
SSA, BCC, SM Phase II a
Phase II
Phase II b
netration, BCC Phase Ib/IIaa,b
Phase III
Phase IIa,b
plex; ELITE = EarLy Inhaled Tobramycin for Eradication Study; EPIC = Early
intravenous; MA = Mycobacterium abscessus; MC = Mycobacterium chelonae;
sistant Staphylococcus aureus; MSSA = methicillin-sensitive Staphylococcus
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disease (FEV1b50% predicted) [109].
4.3.2. Tobramycin inhalation powder (TIP)
TIP is a dry powder that was developed as an alternative to
nebulized tobramycin. Potential advantages over the nebulized
formulation include an administration time of b3 min, an ability
to store medication at room temperature, and no need to clean or
disinfect the delivery device. A study using scintography
demonstrated improved lung deposition with dry powder
compared with nebulized medication [110]. A phase I, multi-
center, single-dose, dose-escalation study compared pharmaco-
kinetics and safety of TIP to tobramycin solution for inhalation
(TSI) in 90 CF subjects [111]. Four capsules (112 mg) of TIP
produced comparable pharmacokinetics to 300 mg TSI. Adverse
events were more common in the TIP group and primarily
consisted of increased cough and dysgeusia. Most adverse events
were mild and self-limited and the authors speculated that if used
chronically, subjects may acclimate to the high inhaled powder
load. Two phase III studies to determine the efficacy and safety of
TIP are now completed and data analysis is ongoing.
4.3.3. Dry powder colistin
Colistin is a polymyxin antibiotic with activity against
P. aeruginosa and low rates of resistance [112]. Nebulized
colistin sulphomethate has been used since the 1980s as inhaled
therapy for CF patients chronically and intermittently colonized
with P. aeruginosa [113,114]. In order to make delivery of the
medication more efficient and less time-consuming for the
patient, dry powder formulations of colistin sulfate and colistin
sulphomethate have been studied [115–117]. [117] A feasibility
study of 25 mg dry powder colistin sulfate in healthy volunteers
and CF patients found moderate to severe cough and decrease in
lung functions in some CF subjects after dry powder inhalation
[118]. Pharmacokinetic data suggested that the dry powder dose
could be decreased to 10 mg while maintaining equivalence to
160 mg nebulized colistin sulphomethate, possibly reducing
adverse events. More recently, Westerman et al. performed a
single-dose pilot study comparing 25 mg dry powder colistin
sulphomethate to 158 mg nebulized colistin in 10 CF subjects
[119]. The dry powder colistin was well tolerated with only
mild cough in some subjects and no decrease in lung functions.
However, the dry powder colistin had a lower AUC, maximum
concentration (Cm) and time to maximum concentration (Tm)
compared to nebulized colistin. The authors speculated that
optimization of the particle size and inspiratory flow rate may
improve pulmonary deposition. A multi-center phase III trial of
dry powder colistin is currently underway in Europe.
4.4. CFTR protein rescue
CFTR mutations may be categorized into 5 classes based on
the mechanism of abnormal function or trafficking [120]. Class I
mutations are nonsense mutations that result from premature
stop codons that terminate ribosomal translation of mRNA into
protein. Class II mutations impair protein processing, resulting
in CFTR degradation and lack of transport to the cell membrane.Class III mutations disrupt functioning of the regulatory domain.
CFTR is transported to the cell membrane, but remains closed
with no chloride transport. Class IV mutations result in
decreased chloride transport through cell membrane proteins,
and Class V mutations are splicing mutations that result in
variable amounts of functioning protein [121]. Therapies
targeting the basic defect of CFTR protein function or
processing are now in development, and ultimately may allow
genotype-specific treatment. These therapies can be divided into
3 general types: (i) molecules that read through premature stop
codons (class I), (ii) correctors that facilitate movement of
CFTR to the cell membrane (class II) and (iii) potentiators that
increase chloride conductance through CFTR (class III and
possibly other classes). Correctors and potentiators may have an
additive effect, and both mechanisms may be needed to achieve
adequate levels of CFTR function for some mutations [122].
Small-molecule CFTR potentiators and correctors are currently
in early clinical trials. One phase II trials of PTC-124, a small
molecule that induces ribosomes to read through premature stop
codons, was recently completed which demonstrated a statisti-
cally significant difference in nasal potential difference
following treatment compared to before treatment [123].
4.5. Mucociliary clearance
CFTR dysfunction impedes chloride ion transport into the
airway lumen, which leads to dehydration of the airway surface
liquid lining the airway epithelium. Increased transepithelial
sodium absorption caused by loss of CFTR's regulatory effect
compounds this factor. Cilia are unable to function properly,
and mucociliary clearance is reduced [4]. In addition,
neutrophilic inflammation leads to high levels of DNA released
from degenerating leukocytes and increased mucus viscosity
[6]. Current therapies include hypertonic saline, which may
improve airway surface hydration [124], and dornase alfa,
which breaks down DNA, and decreases mucus viscosity [125].
Two new treatments currently in clinical trials, denufosol and
inhaled mannitol, are discussed below.
4.5.1. Denufosol
Denufosol tetrasodium is a P2Y2 receptor agonist that
stimulates chloride secretion by activating an alternative
chloride channel in airway epithelium. Denufosol also inhibits
sodium absorption, enhances mucin secretion from goblet cells,
increases ciliary beat frequency, and stimulates surfactant
release from type II alveolar cells [126]. The result is increased
hydration of the airway surface liquid, improved ciliary
function, and more rapid clearance of airway mucus. Phase I
and early phase II studies demonstrated safety and tolerability of
nebulized denufosol in healthy nonsmokers, smokers, and
patients with CF, although some increase in adverse events and
intolerability was noted among CF subjects with lower lung
function (b75%) [127]. A phase II placebo-controlled trial
evaluated the safety and efficacy of denufosol in 89 patients
with CF and mild lung disease (FEV1≥75% of predicted)
[128]. Patients were randomized to received placebo or 1 of 3
doses of denufosol (20, 40, or 60 mg) 3 times daily for 28 days.
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common adverse event was cough, which occurred in similar
numbers of control and treated patients. Patients who received
denufosol demonstrated a significant increase from baseline in
forced vital capacity (FVC), FEV1, and forced mid-expiratory
flow rate (FEF25–75) after 28 days compared with controls.
Two, randomized, placebo-controlled phase III studies are now
under way to evaluate denufosol 60 mg TID in 350 patients
with CF and mild lung disease.
4.5.2. Inhaled mannitol
Inhaled mannitol is an osmotic agent delivered as a dry
powder that may improve mucociliary clearance by drawing
water into the airways. Daviskas et al. demonstrated improved
lung clearance at 2 and 24 h after a single dose of inhaled
mannitol in patients with bronchiectasis [129]. A 2-week,
randomized, double-blind, placebo-controlled crossover study
in 39 patients with CF showed a significant improvement in
FEV1 (change in FEV1, 7.0% vs. 0.3%) and CFQ-R Respiratory
Symptoms in patients given mannitol compared with those who
received placebo [130]. No significant adverse events were
reported. Phase III, multinational randomized trials are ongoing
to determine the safety and efficacy of inhaled mannitol in
patients with CF.
5. CF lung infections: research opportunities
Many research opportunities inCF care are currently available.
Table 4 highlights some of these emerging issues. Below we
discuss in more detail issues specific to CF microbiology
research.
5.1. Polymicrobial infections in CF
The most common bacterial pathogens associated with
chronic lung infections in CF are P. aeruginosa, S. aureus, and
Haemophilus influenzae [131]. Burkholderia cepacia complex,
now known to include≥17 distinct species, are found in a small
percentage of patients with CF, and these pathogens can have
devastating effects on mortality and options for lung transplan-
tation [132]. Stenotrophomonas maltophilia and Achromobacter
xylosoxidans are emerging gram-negative bacterial pathogens
that may have a deleterious effect on the CF-compromised lung
[133,134]. Careful microbial culture of airway samples detects
these pathogens and can guide antimicrobial therapy. In additionTable 4
Research questions in cystic fibrosis (CF).
How canwe use early diagnosis through newborn screening to improve outcomes?
What are the appropriate outcome measures in infants and toddlers?
What is the contribution of pulmonary exacerbation to lung function decline?
What causes the gender difference in outcomes?
What is the clinical impact of polymicrobial infection in CF lung disease?
What is the optimal management of methicillin-resistant Staphylococcus aureus
infection in patients with CF?
Are there biochemical markers of lung injury/damage and destruction?
How can we integrate new therapies into existing management strategies?to routinely cultured bacteria, other potential pathogens include
fungi, viruses, mixed anaerobic bacteria, and nontuberculous
mycobacterium [135–137]. Themost common fungus detected in
CF airway samples, Aspergillus fumigatus, causes allergic
bronchopulmonary Aspergillosis (ABPA) in 1% to 15% of
patients with CF [138]. Patients with A. fumigatuswithout ABPA
may also develop a fungal bronchitis responsive to antifungal
therapy [139].
Increasingly research demonstrates that CF lung infection is
polymicrobial [10]. Patients frequently harbor more than one
pathogen. One prospective study of sputum cultures from 595
patients with CF found 2.9 bacterial pathogens per sample
among 1753 specimens [131]. Fungi and nontuberculous
mycobacterium are also frequently isolated and may interact
with bacterial pathogens. Culture-independent molecular tech-
niques are now available to identify difficult-to-culture bacteria
[140]. Using a molecular approach, Harris et al. examined
bronchoalveolar lavage (BAL) samples from 42 patients,
including 28 with CF [141]. BAL from 13 patients with CF
contained bacteria not routinely assessed by culture, including
anaerobes. Future studies are needed to improve our under-
standing of microbial communities, virulence, and interactions
in CF lung disease.
5.2. Methicillin-resistant Staphylococcus aureus (MRSA)
The prevalence of MRSA has increased over the past decade
from 0.1% in 1995 to 17.2% in 2005 [94]. The impact of MRSA
infection on CF lung disease is still debated [142]. Recently, two
large epidemiologic studies sought to determine the impact of
MRSA infection on lung function decline. In a study of data
collected for the ESCF, researchers examined data from 5090
patients with CF over 2 years [143]. During that time, 12% of
patients had an incident MRSA infection. Patients with MRSA
had lower lung function and more rapid decline in lung function
than patients without MRSA. However, the rate of lung function
decline compared before and afterMRSA detection did not differ.
Therefore, although patientswithMRSAhad lower lung function,
a causative effect fromMRSAwas not demonstrated. The second
study used CFF Patient Registry data to study 17,357 patients
with CF between 1996 and 2005 (average follow-up, 5.3 years)
[144]. This study found a significant increase in rate of lung
function decline in patients with persistent MRSA infection
(defined as ≥3 MRSA-positive cultures) compared with those
without MRSA. Contrary to the ESCF data, this study found that
the rate of lung function decline increased after MRSA detection
compared to the rate of decline before detection. The longer study
period, larger group and use of “persistent” MRSA infection
definitionmay explain some of the difference in findings between
studies. Further research on the impact and optimal management
of MRSA in CF is needed.
5.3. Pseudomonas aeruginosa serology
As treatment for P. aeruginosa eradication becomes standard
care, outcome measures to define infection and eradication
states for this pathogen are needed. Eradication strategies rely
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for both determining who needs treatment and assessing
efficacy of therapy. Serum antibodies may be helpful, especially
if they are elevated prior to a positive culture and decrease with
successful eradication. However, while some studies have
found an increase in serum antibodies before first detection by
airway culture, other studies have not confirmed this finding
[145–147]. Ratjen et al. recently determined cutoff values for
three anti-pseudomonal antibodies, alkaline protease, exotoxin
A, and elastase by studying serum samples from 375 patients
with CF and known P. aeruginosa status (negative, chronic, or
intermittently infected) [148]. In a second cohort of 56 patients
with CF who had new-onset infection undergoing eradication
therapy, it was found that 42% had positive antibodies at the
time of initial positive culture. Following eradication treatment,
patients who were successfully treated had a significant
decrease in mean antibody titers, while those who failed
eradication showed an increase in titer levels. Thus, although
serum antibodies had a low sensitivity for detecting early
infection with P. aeruginosa, they may be useful for monitoring
response to eradication therapy. Future studies are planned,
using the combination of alkaline protease, exotoxin A, and
elastase antibodies as part on ongoing eradication intervention
trials. Likely a combination of culture, molecular diagnostics,
and serology may provide the best sensitivity for early
P. aeruginosa detection [149].
6. Conclusion
Although CF remains a life-shortening condition associated
with significant morbidity, recent advances and new treatments
offer great hope and promise. Expanded newborn screening
programs and improvements in early disease management may
delay disease progression in future cohorts; an increasing
number of adults with CF are living with more mild disease and
are engaged in normal work and family roles. Treatment of
chronic lung infection will likely improve with new antimicro-
bials, better delivery mechanisms for existing antibiotics, and
better microbial detection. Patient-reported outcome measures
provide data on the effects of new medications, as well as an
increased understanding of how CF affects daily functioning.
Many barriers still remain for patients, clinicians, and
researchers. Poor adherence is a significant contributor to
treatment failures and will require implementation of practical-,
clinic- and family-based interventions. Quality improvement
initiatives are expanding to improve outcomes with currently
available treatments. Continued research is needed to identify
optimal outcome measures for clinical trials.
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